Form 4: ResMed CFO Sells Shares Under Pre-Arranged Trading Plan

ResMed Inc.'s Chief Financial Officer, Brett Sandercock, sold 3,644 shares of common stock for approximately $891,500 under a pre-established Rule 10b5-1 trading plan.

Summary

• Brett Sandercock, Chief Financial Officer of ResMed Inc. (RMD), reported a transaction involving the company's common stock.
• On May 22, 2025, Mr. Sandercock disposed of 3,644 shares of ResMed Common Stock at a price of $244.59 per share.
• This transaction was conducted pursuant to a Rule 10b5-1 plan, which was adopted on February 19, 2025.
• Following this transaction, Mr. Sandercock beneficially owns 86,283 shares of ResMed common stock.
• The reported beneficial ownership includes 62.6994 shares of ResMed stock purchased on April 30, 2025, through the ResMed Employee Stock Purchase Plan.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While it's an insider sale, the fact that it's under a Rule 10b5-1 plan indicates transparency and pre-planning, which is generally viewed favorably. The CFO also continues to hold a significant number of shares and recently purchased more through an ESPP.

Positives

• The transaction was executed under a Rule 10b5-1 plan, indicating a pre-scheduled and transparent sale, which helps mitigate concerns about opportunistic insider trading.
• The CFO's continued significant beneficial ownership of 86,283 shares demonstrates ongoing alignment with shareholder interests.
• The purchase of 62.6994 shares through the Employee Stock Purchase Plan on April 30, 2025, indicates continued participation and investment by the CFO in the company's stock.

Negatives

• An insider sale, even if pre-planned, can sometimes be perceived negatively by investors as it reduces the insider's direct equity stake in the company.

Future Outlook

This document does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This Form 4 filing is a routine disclosure of an insider stock transaction and does not provide broader insights into industry trends or competitive landscape. It reflects an individual executive's pre-planned equity management.

Stakeholder Impact

• Shareholders: The sale by a key executive could be viewed with slight caution, but the pre-planned nature via a 10b5-1 plan mitigates concerns about negative implications. The CFO's continued significant holding suggests ongoing alignment.

Key Dates

Keywords

ResMed Inc., RMD, SEC Form 4, Insider Trading, Stock Sale, Rule 10b5-1 Plan, Chief Financial Officer, Brett Sandercock, Employee Stock Purchase Plan